Posts
High prevalence pertussis is expected to propel growth of
the prescription narcotic cough preparations and expectorants market. For
instance, according to the World Health Organization, there were 132,754
reported cases of pertussis worldwide in 2019. Moreover, high prevalence of
chronic cough is also expected to aid in growth of the market. For instance, according
to the study, ‘Prevalence
and Characteristics of Chronic Cough in Adults Identified by Administrative
Data’ published in Parmanente Journal in 2020, the overall prevalence was
chronic cough was 1.04% in 2016. Moreover, the prevalence was higher in female
patients than in male patients.
Permission for prescribing controlled substances through
telemedicine is expected to offer lucrative growth opportunities for players in
the prescription narcotic cough preparations and expectorants
market. For
instance, in 2020, the U.S. Drug Enforcement Administration permitted issuance
of prescriptions for controlled substances via a telemedicine encounter in the
wake of COVID-19 pandemic. Moreover, implementation of prescription drug
monitoring programs is also expected to aid in growth of the market. Most
states in the U.S. use an electronic database to help reduce misuse and
diversion of controlled substances.
However, illicit sale of Codeine-based cough syrups is
expected to hinder growth of the prescription narcotic cough preparations and
expectorants market. The market is also witnessing increasing misuse of
prescription and over-the-counter drugs for recreational purposes, thereby
limiting its growth.
Ban or restrictions on manufacture, sale, and distribution
of fixed dose combination drugs in some countries is also expected to limit the
market growth. For instance, in 2018, the U.S. Food and Drug Administration
advised against recommending cough medications that contain opioids to
children.
The prescription narcotic cough preparations and
expectorants market in North America is facing the challenge of pharmacy
break-ins as narcotic cough preparations and expectorants cannot be acquired
without a prescription. In February 2020, California Board of Pharmacy, U.S,
stated that pharmacy break-ins increased from 114 in 2015 to 265 in 2018,
recording a 49% increase.
Competitive Analysis
Major players operating in the prescription narcotic cough
preparations and expectorants market include, Glenmark Pharmaceuticals Ltd.,
Franklin Laboratories Pvt. Ltd., Pans Laboratories, Synokem Pharmaceuticals
Ltd., Lyka Hetero Healthcare Limited, Biomedica International, Klar Sehen Pvt.
Ltd., and Ciron Drugs & Pharmaceuticals Pvt. Ltd.
No comments:
Post a Comment